NCT03652363View on ClinicalTrials.gov

GDNF in ideopathicParkinsons Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 25, 2012

Primary Completion Date

March 13, 2015

Study Completion Date

April 1, 2016

Conditions
Idiopathic Parkinson Disease
Interventions
DRUG

glial cell line-derived neurotrophic factor

Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery

All Listed Sponsors
lead

North Bristol NHS Trust

OTHER

NCT03652363 - GDNF in ideopathicParkinsons Disease | Biotech Hunter | Biotech Hunter